VRCA Stock — Verrica Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$4.45

Market cap

$76.4M

Cash

$11.2M

Enterprise value

$65.2M

Balance sheet

Cash	$11.2M
Debt	$0.0M
Net cash	$11.2M
Enterprise value	$65.2M
Basic shares	17.2M shares
Fully diluted shares	20.1M shares
Fully diluted market cap	$89.4M
Cash per share	$0.65

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading VRCA daily closes…

Loading price history…

Pipeline assets

YCANTH

Approved · Active Modality: topical

Aliases VP-102, TO-208, cantharidin 0.7% topical solution

Partnerships Torii/Shionogi (Japan; exclusive license for cantharidin products for molluscum and common warts; YCANTH/TO-208 approved in Japan Sep 2025, launched Feb 2026)

Indications

Molluscum contagiosum (Approved)
Common warts (Phase 2)

Status note First FDA-approved product for molluscum (Jul 2023, ages 2+); commercially launched in U.S. Aug 2023. Phase 2 COVE-1 in common warts completed; Type C meeting held. Cash of $11.2M at Jun 30, 2026 with $12.5M credit facility (PD Credit Agreement, Aug 2026).

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	VP-102 (US) / TO-208 (Japan)
Lead indication	Common Warts
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07637734	Phase 3	Recruiting	Sponsor	VRCA	—	Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV)	—
NCT07246590	Phase 3	Recruiting	Sponsor	VRCA	—	Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV)	—
NCT07457918	Phase 3	Recruiting	Sponsor	VRCA	—	Common Warts (Verruca Vulgaris); Common Warts; Human Papilloma Virus (HPV)	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Verrica Pharmaceuticals Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

VRCA — Verrica Pharmaceuticals Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials